NYSE:ABBV - AbbVie Stock Price, News, & Analysis

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie declared a quarterly dividend on Thursday, February 21st. Investors of record on Monday, April 15th will be paid a dividend of $1.07 per share on Wednesday, May 15th. This represents a $4.28 dividend on an annualized basis and a yield of 5.35%. The ex-dividend date is Friday, April 12th. View AbbVie's Dividend History.

AbbVie declared that its Board of Directors has initiated a share repurchase program on Thursday, December 13th 2018, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 3.8% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued.

AbbVie Inc (NYSE:ABBV) released its quarterly earnings results on Thursday, April, 25th. The company reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.08. The company earned $7.83 billion during the quarter, compared to analysts' expectations of $7.81 billion. AbbVie had a negative return on equity of 221.09% and a net margin of 16.42%. The company's quarterly revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.87 EPS. View AbbVie's Earnings History.

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, July 26th 2019. View Earnings Estimates for AbbVie.

AbbVie updated its FY19 earnings guidance on Thursday, April, 25th. The company provided EPS guidance of $8.73-8.83 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $8.67. AbbVie also updated its FY 2019 guidance to $8.73-8.83 EPS.

16 brokers have issued 1-year target prices for AbbVie's stock. Their forecasts range from $65.61 to $135.00. On average, they expect AbbVie's stock price to reach $94.5871 in the next year. This suggests a possible upside of 18.1% from the stock's current price. View Analyst Price Targets for AbbVie.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 4 sell ratings, 8 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AbbVie.

Press coverage about ABBV stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AbbVie earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 8.0 out of 10, indicating that recent media coverage is very likely to have an impact on the stock's share price in the next several days.

AbbVie saw a decrease in short interest in April. As of April 30th, there was short interest totalling 21,822,012 shares, a decrease of 20.9% from the April 15th total of 27,575,807 shares. Based on an average daily volume of 7,260,751 shares, the days-to-cover ratio is presently 3.0 days. Currently, 1.5% of the shares of the stock are sold short. View AbbVie's Current Options Chain.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY) and Shire (SHPG).

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Valeant Pharmaceuticals Intl (VRX) and Toronto-Dominion Bank (TD).

AbbVie's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.44%), Geode Capital Management LLC (1.45%), Northern Trust Corp (1.37%), FMR LLC (0.89%), Janus Henderson Group PLC (0.68%) and Morgan Stanley (0.61%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Glenn F Tilton, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Aristotle Capital Management LLC, Northern Trust Corp, PNC Financial Services Group Inc., BlackRock Inc., Ferguson Wellman Capital Management Inc., Handelsbanken Fonder AB and Clark Capital Management Group Inc.. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Brian L Durkin, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

ABBV stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Geode Capital Management LLC, Ellis Investment Partners LLC, Renaissance Technologies LLC, Ronna Sue Cohen, Parnassus Investments CA, Federated Investors Inc. PA and AQR Capital Management LLC. Company insiders that have bought AbbVie stock in the last two years include Edward J Rapp and Glenn F Tilton. View Insider Buying and Selling for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $80.06.

AbbVie has a market capitalization of $118.36 billion and generates $32.75 billion in revenue each year. The company earns $5.69 billion in net income (profit) each year or $7.91 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

The official website for AbbVie is http://www.abbvie.com/.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.